ArticleCancer medicine2026
A Geographic Disparities Analysis Between Standard of Care and Clinical Trial CAR-T Patients in Kansas.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundThis study compares demographics and geographic factors associated with access to chimeric antigen receptor (CAR)-T cell therapy for B-cell malignancies or multiple myeloma: individuals in clinical trials at the University of Kansas Cancer Center (KUCC) and those receiving standard-of-care (SOC) CAR-T at the University of Kansas Health System (TUKHS).
methodsData were collected from electronic medical records and the KUCC Clinical Trial Management System. We evaluated differences in CAR-T access across race, gender, age, rurality, and HPSA status. SOC patients received FDA-approved CAR-T between May 2021 and May 2023; clinical trial patients received investigational CAR-T between January 2015 and February 2023.
resultsMost patients (80%) were from urban areas; 54.1% lived within 50 miles of the University of Kansas Medical Center (KUMC). The cohort was 58.4% male, 86.7% white, 60.4% aged 19-64, and 57% lived outside a Health Professional Shortage Area (HPSA). Rural patients made up 20% of both cohorts. No significant demographic differences were observed between clinical trial and SOC recipients. However, rural residence was significantly associated with age 65 or older (OR = 1.80), white race, HPSA status, and living more than 50 miles from KUMC (OR = 27.01). HPSA status was also associated with greater odds of living beyond the 50-mile radius (OR = 2.29).
conclusionsFindings highlight important geographic disparities in CAR-T access. Targeted outreach to rural and HPSA-designated communities may improve equity and ensure broader access to advanced therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.